A systematic review and meta‐analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The aim of this study is to assess the efficacy and safety of lixisenatide for treating type 2 diabetes. A systematic search in electronic databases (up to October 2012) was conducted and the manufacturer was contacted regarding unpublished data. Randomized controlled trials ( RCTs ) were included if they provided information on at least one of the following outcomes: mortality, health‐related quality of life, hypoglycaemic events, adverse events, change in HbA1c , body weight, blood pressure, gastric emptying, fasting plasma glucose or 2 h postprandial glucose (PPG). Twenty‐six publications and 10 unpublished study reports, relating to 14 RCTs (6156 patients) were included. Eleven studies related to placebo comparisons; active comparators were in three studies. Compared to placebo, lixisenatide significantly reduced HbA1c (−0.52%; 95% CI : −0.64 to −0.39), bodyweight (−0.65 kg; 95% CI : −0.94 to −0.37) and 2‐h PPG level (−4.58 mmol/l; 95% CI : −5.88 to −3.28). There were significantly more symptomatic hypoglycaemic events among lixisenatide compared to placebo‐treated patients (log OR : 0.54; 95% CI : 0.32–0.75), but significantly fewer compared to other incretin mimetics. In comparison to exenatide and liraglutide, lixisenatide was more effective in reducing 2 h‐ PPG with a better adverse events profile, but it showed a lower reduction in HbA1c and body weight. Lixisenatide improves HbA1c levels and moderately reduces body weight compared to placebo and showed less frequent symptomatic hypoglycaemic and gastrointestinal events and an improvement in PPG control compared to other GLP ‐1 agonists. Firm conclusions regarding the performance of lixisenatide compared to other incretin mimetics, however, can not yet be drawn, due to limited data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved tests for a random effects meta‐regression with a single covariate
Knapp, G., & Hartung, J. (2003) · Statistics in Medicine · doi:10.1002/sim.1482 · Cited by 2,075 · cited 1×
“Test statistics and confidence intervals were adjusted using previously established methods [11].”
MethodGlucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Levitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668
Cavalot, F., Petrelli, A., Traversa, M., Bonomo, K., Fiora, E., Conti, M., Anfossi, G., Costa, G., & Trovati, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1005 · Cited by 569
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · cited 1×
“In addition to improved HbA1c control, benefits of GLP-1 agonists include reduced hypoglycaemic events and beneficial effects on weight, although they are associated with adverse gastrointestinal effects [6].”
BackgroundEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Bonora, E., Corrao, G., Bagnardi, V., Ceriello, A., Comaschi, M., Montanari, P., & Meigs, J. B. (2006) · Diabetologia · doi:10.1007/s00125-006-0203-x · Cited by 141 · cited 1×
“Postprandial hyperglycaemia is commonly observed among patients with diabetes [58–61], even among patients showing well-controlled HbA1c levels [59,60] and epidemiological studies have shown a link between blood sugar levels following meals and the risk of the onset of cardiovascular disease [62–65] or retinopathy [66…”
Background
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“Lixisenatide is a new once-daily agonist with a high affinity for the GLP-1 receptor and particularly strong effects on postprandial plasma glucose levels [98, 99].”
BackgroundWeight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Metadata
- Authors
- Schmidt, L. J., Habacher, W., Augustin, T., Krahulec, E., & Semlitsch, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-02-24
- Volume
- 16
- Issue
- 9
- Pages
- 769-779
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2120128459
- Cited by
- 31
- References
- 12
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review and meta‐analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12269
- The paper
- Schmidt, L. J., Habacher, W., Augustin, T., Krahulec, E., & Semlitsch, T. (2014). A systematic review and meta‐analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.